Autologous mesenchymal stem cell transplantation in stroke patients
By Oh Young Bang, Jin Soo Lee, Phil Hyu Lee, Gwang Lee. Annals of Neurology, 2005
1,084 citations recorded by the source corpus.
Mesenchymal stem cell (MSC) transplantation improves recovery from ischemic stroke in animals. We examined the feasibility, efficacy, and safety of cell therapy using culture‐expanded autologous MSCs in patients with ischemic stroke. We prospectively and randomly allocated 30 patients with cerebral infarcts within the middle cerebral arterial territory and with severe neurological deficits into one of two treatment groups: the MSC group (n = 5) received intravenous infusion of 1 × 108 autologous MSCs, whereas the control group (n = 25) did not receive MSCs. Changes in neurological deficits and improvements in function were compared between the groups for 1 year after symptom onset. Neuroimaging was performed serially in five patients from each group. Outcomes improved in MSC‐treated patients compared with the control patients: the Barthel index (p = 0.011, 0.017, and 0.115 at 3, 6, and 12 months, respectively) and modified Rankin score (p = 0.076, 0.171, and 0.286 at 3, 6, and 12 months, respectively) of the MSC group improved consistently during the follow‐up period. Serial evaluations showed no adverse cell‐related, serological, or imaging‐defined effects. In patients with severe cerebral infarcts, the intravenous infusion of autologous MSCs appears to be a feasible and safe therapy that may improve functional recovery. Ann Neurol 2005;57:874–882
Subfields: Developmental Neuroscience, Genetics, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/95260ac72feb4f894bbcde163feeb8843ccae1a5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- A Long‐Term Follow‐Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke (2010, methodology): “2 lines), and clinical trials of neuronal differentiated tumor cell lines [2], neural progenitor cells from primordial porcine striatum [3] and autologous bone marrowderived mesenchymal stem cells (MSCs) [4] have been conducted.”
- Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages (2009, background): “In many phase I and II clinical studies MSCs, autologous or allogeneic, have been shown to be potentially efficacious for treatment of a wide variety of clinical conditions such as acute graft versus host disease after allogeneic hematopoietic stem cell transplantation [40,41], myocardial, infarctio”